Previous close | 0.3906 |
Open | 0.3906 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 0.3906 - 0.3906 |
52-week range | 0.1694 - 8.1500 |
Volume | |
Avg. volume | 442 |
Market cap | 13.793M |
Beta (5Y monthly) | 1.07 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.5370 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.
Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.